tradingkey.logo

Immunitybio Inc <IBRX.OQ> expected to post a loss of 13 cents a share - Earnings Preview

ReutersMay 9, 2025 8:34 PM
  • Immunitybio Inc IBRX.OQ IBRX.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • The San Diego California-based company is expected to report a 39,937.5% increase in revenue to $16.015 million from $40 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Immunitybio Inc is for a loss of 13 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Immunitybio Inc is $8.00​, above​ its last closing price of $2.09. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.19

-0.20

-0.09

Beat

55

Sep. 30 2024

-0.18

-0.18

-0.12

Beat

33.3

Jun. 30 2024

-0.17

-0.20

Missed

-17.6​

Mar. 31 2024

-0.16

-0.20

Missed

-25

​​Dec. 31 2023

-0.18

-0.35

Missed

-94.4

Sep. 30 2023

-0.25

-0.19

Beat

25.5​

Jun. 30 2023

-0.23

-0.23

-0.32

Missed

-36.2

-0.27

This summary was machine generated May 9 at 20:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI